Read by QxMD icon Read


Olivier Chapet, Corina Udrescu, Samy Horn, Alain Ruffion, Fabrice Lorchel, Sonya Gaudioz, Cécile Clamens, Vincent Piriou, Edwige Rigal
PURPOSE: Hypnosedation (HS) for brachytherapy has been proposed in patients with prostate cancer and has been evaluated. MATERIALS AND METHODS: 79 patients were treated with brachytherapy under HS. The Visual Analog Scale questionnaire was used to assess comfort and anxiety and the lowest, mean, and highest level of pain. Data for 79 patients who underwent general anesthesia (GA) and 37 patients who underwent spinal anesthesia (SA) treated at the same period were compared with HS group in terms of medication and treatment duration...
November 10, 2018: Brachytherapy
Cynthia Aristei, Valentina Lancellotta, Marco Piergentini, Giacomo Costantini, Simonetta Saldi, Sara Chierchini, Antonella Cavalli, Luca Di Renzo, Oscar Fiorucci, Massimo Guasticchi, Vittorio Bini, Alessandro Ricci
PURPOSE: High-dose-rate, multicatheter interstitial brachytherapy is technically complex and operator-dependent, requiring lengthy training and specialized skills. Furthermore, until the advent of contouring on computerized tomography (CT) images, difficulties existed in locating the target volume precisely. The present article reports the results of a study that aimed at producing and validating a 3D-printed template to aid in target volume localization for multicatheter interstitial brachytherapy in patients with breast cancer...
November 7, 2018: Brachytherapy
An-Sofie Verrijssen, Thirza Opbroek, Murillo Bellezzo, Gabriel P Fonseca, Frank Verhaegen, Jean-Pierre Gerard, Arthur Sun Myint, Evert J Van Limbergen, Maaike Berbee
PURPOSE: A clinical complete response is seen after neoadjuvant chemoradiation for rectal tumors in 15%-20% of patients. These patients can potentially be spared mutilating total mesorectal excision surgery through a watch-and-wait policy. Recent studies show that dose escalation by a radiation boost increases the clinical complete response rate. The boost dose to the tumor can be administered through external beam radiotherapy or through internal radiotherapy using techniques like contact therapy, low-dose-rate or high-dose-rate brachytherapy (BT)...
November 2, 2018: Brachytherapy
Dylann K Fujimoto, Rie von Eyben, Melissa Usoz, Elizabeth A Kidd
PURPOSE: To investigate the different factors affecting the procedure duration for high-dose-rate brachytherapy for gynecologic malignancies. METHODS AND MATERIALS: We prospectively recorded 86 consecutive vaginal cylinder (VC) treatments and 82 tandem and ovoid treatments. Key time points in the brachytherapy process, identity of the planner and checker, number of treatments per day, and fraction number per patient were recorded. The data were analyzed in a mixed effects linear regression model to account for the within patient correlation...
October 31, 2018: Brachytherapy
Jazan Omari, Ralph Drewes, Manig Matthias, Konrad Mohnike, Max Seidensticker, Ricarda Seidensticker, Tina Streitparth, Jens Ricke, Maciej Powerski, Maciej Pech
PURPOSE: Evaluation of efficacy and safety of CT- or MRI-guided high-dose-rate interstitial brachytherapy (iBT) in the treatment of advanced, imatinib refractory, metastatic gastrointestinal stroma tumors (GISTs) was the objective of this retrospective study. METHODS AND MATERIALS: A cumulative number of 40 unresectable metastases (30 hepatic, 10 peritoneal) were treated with iBT in 10 selected patients with histologically proven GISTs. Six patients had peritoneal disease, and 5 patients were even progressing under sunitinib (second line)-thus iBT was applied as a salvage maneuver...
October 29, 2018: Brachytherapy
Bin Cai, Michael B Altman, Francisco Reynoso, Jose Garcia-Ramirez, Angell He, Sharbacha S Edward, Imran Zoberi, Maria A Thomas, Hiram Gay, Sasa Mutic, Jacqueline E Zoberi
PURPOSE: To standardize and automate the high-dose-rate (HDR) brachytherapy planning quality assurance (QA) process utilizing scripting with application programming interface (API) in a commercially available treatment planning system (TPS). METHODS AND MATERIALS: Site- and applicator-dependent plan quality (PQ) evaluation criteria and plan integrity (PI) checklists were established based on published guidelines, clinical protocols, and institutional experience...
October 29, 2018: Brachytherapy
Bridget A Quinn, Xiaoyan Deng, Adrianne Colton, Dipankar Bandyopadhyay, Jori S Carter, Emma C Fields
PURPOSE: Stage and histology are well-established prognostic factors for cervical cancer, but the importance of age has been controversial and a clear role for this factor has not yet been defined. Thus, we aim with this study to evaluate the significance of age as an independent prognostic factor in women with cervical cancer and evaluate the therapeutic consequences and survival outcomes as they relate to this factor. METHODS AND MATERIALS: The Surveillance, Epidemiology, and End Results (SEER) database was used to retrospectively analyze patients diagnosed with cervical cancer from 1973 to 2013 in the United States...
October 22, 2018: Brachytherapy
Daphna Y Spiegel, Fumiko Chino, Haley Moss, Laura J Havrilesky, Junzo P Chino
PURPOSE: The Patient Protection and Affordable Care Act called for expansion of Medicaid in 2014. As some states elected to expand Medicaid and others did not, the goal of this study was to determine the effect of Medicaid expansion on the insurance status at cancer diagnosis of brachytherapy patients. METHODS AND MATERIALS: Patients aged 19-64 years with breast, cervical, uterine, or prostate cancer treated with brachytherapy from 2011 to 2014 with known insurance status were identified within the Surveillance, Epidemiology, and End Results registry...
October 20, 2018: Brachytherapy
Lucas C Mendez, Pencilla Lang, Chirag Patel, David D'Souza, Adam Gladwish, Laura D'Alimonte, Amandeep Taggar, Elizabeth Barnes, Lisa Barbera, Eric Leung
PURPOSE: Perineal interstitial brachytherapy (P-ISBT) is an important component in the treatment of locally advanced gynecological cancers. However, there are concerns about potential acute complications from catheter needles. The goal is to evaluate the safety of P-ISBT by studying acute complications and radiological organ needle intrusions. MATERIALS AND METHODS: Forty-eight patients with gynecological cancers treated with P-ISBT at a single institution from September 2014 to April 2016 were included in a prospective registry trial...
October 10, 2018: Brachytherapy
Minsi Zhang, T Jonathan Yang, Neil B Desai, Deborah DeLair, Marisa A Kollmeier, Vicky Makker, Mario M Leitao, Nadeem R Abu-Rustum, Kaled M Alektiar
PURPOSE: The treatment paradigm for uterine clear cell carcinoma is often linked to serous carcinoma. This study compares oncologic outcomes between women with uterine clear cell and serous carcinoma. METHODS AND MATERIALS: We reviewed 114 women with stage I-II uterine clear cell carcinoma (n = 17, 15%) or serous carcinoma (n = 97, 85%) who underwent hysterectomy and salpingo-oophorectomy at our institution from April 1992 to December 2011; 86 (76%) had stage IA, 14 (12%) had stage IB, and 14 (12%) had stage II disease...
October 10, 2018: Brachytherapy
David M Routman, Ryan K Funk, Bradley J Stish, Lance A Mynderse, Torrence M Wilson, Robert McLaren, W Scott Harmsen, Kristin Mara, Christopher L Deufel, Keith M Furutani, Michael G Haddock, Thomas M Pisansky, C Richard Choo, Brian J Davis
PURPOSE: To report outcomes of patients undergoing low-dose-rate (LDR) brachytherapy and investigate factors associated with biochemical failure and survival. METHODS: Consecutive patients undergoing LDR with I-125 at our institution between 1998 through 2013 for primary intact prostate cancer were examined. Those with low- and intermediate-risk disease receiving LDR with a minimum of 2 years followup and at least one post-LDR prostate-specific antigen (PSA) were included...
October 4, 2018: Brachytherapy
Amani Shaaer, Melanie Davidson, Mark Semple, Alexandru Nicolae, Lucas Castro Mendez, Hans Chung, Andrew Loblaw, Chia-Lin Tseng, Gerard Morton, Ananth Ravi
PURPOSE: Identifying dominant intraprostatic lesions (DILs) on transrectal ultrasound (TRUS) images during prostate high-dose-rate brachytherapy (HDR-BT) treatment planning is challenging. Multiparametric MRI (mpMRI) is the tool of choice for DIL identification; however, the geometry of the prostate on mpMRI and on the TRUS may differ significantly, requiring image registration. This study evaluates the efficacy of an in-house software for MRI-to-TRUS DIL registration (MR2US) and compares its results to rigid and B-Spline deformable registration...
October 1, 2018: Brachytherapy
Robert H Press, Tiffany M Morgan, Patrick K Cutrell, Chao Zhang, Zhengjia Chen, Sara Rahnema, Martin Sanda, John Pattaras, Pretesh Patel, Ashesh B Jani, Peter J Rossi
PURPOSE: Patients with large prostate glands are underrepresented in clinical trials incorporating brachytherapy due to concerns for excessive toxicity. We sought to compare health-related quality of life (HRQOL) outcomes between small (<60 cc) and large (≥60 cc) prostates treated with high-dose-rate brachytherapy (HDR-B). METHODS AND MATERIALS: One hundred thirty patients at Emory University were treated with HDR-B monotherapy (n = 75) or HDR-B in combination with external beam radiation therapy (n = 55)...
September 25, 2018: Brachytherapy
Jacob S Witt, Robert W Gao, Lisa J Sudmeier, Stephen A Rosenberg, David M Francis, Charles R Wallace, Rupak K Das, Bethany M Anderson
PURPOSE: Studies have shown that an additional mean dose of 1 Gy to the heart can increase the relative risk of cardiac events. The purpose of this study was to quantify the dose delivered to the heart and left anterior descending artery (LAD) in a series of patients with left-sided breast cancer (BC) or ductal carcinoma in situ treated with multicatheter-accelerated partial breast irradiation (MC-APBI) at a single institution. METHODS AND MATERIALS: Patients with left-sided BC or ductal carcinoma in situ treated consecutively from 2005 to 2011 with MC-APBI were retrospectively identified...
September 24, 2018: Brachytherapy
Naoya Niwa, Kazuhiro Matsumoto, Toru Nishiyama, Yasuto Yagi, Choichiro Ozu, Ken Nakamura, Shiro Saito, Mototsugu Oya
PURPOSE: To identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped. METHODS AND MATERIALS: We retrospectively reviewed clinicopathologic data of patients with prostate cancer who underwent LDR-BT between 2003 and 2011. Of 1569 patients reviewed, 689 (43.9%) received combination external beam radiotherapy, and 970 (61...
September 20, 2018: Brachytherapy
W James Morris, Tom Pickles, Mira Keyes
PURPOSE: To compare biochemical failure using a prostate-specific antigen (PSA) threshold of >0.2 ng/mL to that using Phoenix threshold (nadir+2 ng/mL). METHODS AND MATERIALS: Androgen suppression combined with elective nodal and dose-escalated radiation therapy (the ASCENDE-RT trial) is a randomized control trial in which 276 high-risk and 122 intermediate-risk patients were randomized to (1) a standard arm with 12 months of androgen deprivation therapy, pelvic external beam radiation therapy (EBRT) to 46 Gy, and an EBRT boost (dose-escalated EBRT [DE-EBRT]) to 78 Gy, or (2) an experimental arm which substituted a low-dose-rate prostate brachytherapy boost (LDR-PB)...
September 20, 2018: Brachytherapy
YuHuei Jessica Huang, Fan-Chi Frances Su, David K Gaffney, Kristine E Kokeny, Hui Zhao, Prema Rassiah-Szegedi, Bill J Salter, Matthew M Poppe
PURPOSE: To propose a workflow that uses ultrasound (US)-measured skin-balloon distances and virtual structure creations in the treatment planning system to evaluate the maximum skin dose for patients treated with Contura Multi-Lumen Balloon applicators. METHODS AND MATERIALS: Twenty-three patients were analyzed in this study. CT and US were used to investigate the interfractional skin-balloon distance variations. Virtual structures were created on the planning CT to predict the maximum skin doses...
September 17, 2018: Brachytherapy
Sara Abdollahi, Mahdieh Dayyani, Elie Hoseinian-Azghadi, Hashem Miri-Hakimabad, Laleh Rafat-Motavalli
PURPOSE: Although the dosimetric characterization of 60 Co BEBIG source can be found in several literature studies, the data sets show major discrepancies and the lack of uncertainty analyses. This study tried to determine an accurate dosimetric data set for this source using Monte Carlo (MC) simulations along with detailed uncertainty analysis. To explore how different dosimetric data sets can make changes in practical situations, clinical dose distributions based on our results were compared with the dose distributions derived from Granero et al...
September 15, 2018: Brachytherapy
Denisa Pohanková, Igor Sirák, Pavel Jandík, Linda Kašaova, Jakub Grepl, Petr Motyčka, Ahmed Asqar, Petr Paluska, Vladimír Ninger, Ivana Bydžovská, Viliam Kopecky, Jiří Petera
PURPOSE: To assess the feasibility of high-dose-rate perioperative multicatheter interstitial brachytherapy to deliver accelerated partial breast irradiation (APBI) in selected patients with early breast cancer. METHODS AND MATERIALS: Perioperative multicatheter interstitial brachytherapy for APBI has been used at our department since 2012 for patients with low-risk breast cancer. Interstitial catheters were inserted perioperatively via hollow needles immediately following tumorectomy with sentinel node biopsy...
September 15, 2018: Brachytherapy
Karina Nieto, Brendan Martin, Nghia Pham, Laura Palmere, Scott R Silva, Abigail Winder, Margaret Liotta, Ronald K Potkul, William Small, Matthew M Harkenrider
PURPOSE: To compare radiation toxicity in endometrial cancer patients treated with adjuvant vaginal brachytherapy (VBT) vs. VBT with concurrent chemotherapy (CCT) or sequential chemotherapy (SCT) METHODS: We retrospectively analyzed 131 patients with endometrial cancer treated with VBT without external beam radiation therapy. Toxicities were graded according to the Common Terminology Criteria for Adverse Events v4.03. CCT was defined as VBT delivered between the first and last cycle of chemotherapy (CT); SCT was defined as VBT delivered before or after CT...
September 15, 2018: Brachytherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"